10147-12-3 Usage
Uses
Used in Antiviral Therapy:
9H-Purin-6-amine, 9-b-D-arabinofuranosyl-2-chlorois utilized as an antiviral agent for the treatment of herpes simplex and herpes zoster infections. It functions by interfering with the replication and transcription of viral DNA, which helps in controlling the infection and preventing its progression.
Used in Combination Therapy:
9H-Purin-6-amine, 9-b-D-arabinofuranosyl-2-chloromay be administered in conjunction with other antiviral medications to enhance its efficacy and achieve maximum therapeutic outcomes. The combination therapy approach can be particularly beneficial in managing drug-resistant strains of the virus or in cases where a more potent treatment is required.
Used in Intravenous and Topical Administration:
9H-Purin-6-amine, 9-b-D-arabinofuranosyl-2-chlorocan be administered through intravenous or topical routes, depending on the severity and nature of the infection. This flexibility in administration methods allows for tailored treatment approaches based on individual patient needs and the specific characteristics of the infection.
Used in Pharmaceutical Research and Development:
Given its potential in managing viral infections, 9H-Purin-6-amine, 9-b-D-arabinofuranosyl-2-chlorois also used in pharmaceutical research and development for the exploration of new antiviral therapies. Its properties and mechanisms of action provide a foundation for further studies aimed at improving antiviral treatments and addressing the evolving challenges posed by viral resistance.
Check Digit Verification of cas no
The CAS Registry Mumber 10147-12-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,1,4 and 7 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 10147-12:
(7*1)+(6*0)+(5*1)+(4*4)+(3*7)+(2*1)+(1*2)=53
53 % 10 = 3
So 10147-12-3 is a valid CAS Registry Number.
10147-12-3Relevant academic research and scientific papers
Enzymatic Synthesis of Therapeutic Nucleosides using a Highly Versatile Purine Nucleoside 2’-DeoxyribosylTransferase from Trypanosoma brucei
Pérez, Elena,Sánchez-Murcia, Pedro A.,Jordaan, Justin,Blanco, María Dolores,Manche?o, José Miguel,Gago, Federico,Fernández-Lucas, Jesús
, p. 4406 - 4416 (2018/09/14)
The use of enzymes for the synthesis of nucleoside analogues offers several advantages over multistep chemical methods, including chemo-, regio- and stereoselectivity as well as milder reaction conditions. Herein, the production, characterization and utilization of a purine nucleoside 2’-deoxyribosyltransferase (PDT) from Trypanosoma brucei are reported. TbPDT is a dimer which displays not only excellent activity and stability over a broad range of temperatures (50–70 °C), pH (4–7) and ionic strength (0–500 mM NaCl) but also an unusual high stability under alkaline conditions (pH 8–10). TbPDT is shown to be proficient in the biosynthesis of numerous therapeutic nucleosides, including didanosine, vidarabine, cladribine, fludarabine and nelarabine. The structure-guided replacement of Val11 with either Ala or Ser resulted in variants with 2.8-fold greater activity. TbPDT was also covalently immobilized on glutaraldehyde-activated magnetic microspheres. MTbPDT3 was selected as the best derivative (4200 IU/g, activity recovery of 22 %), and could be easily recaptured and recycled for >25 reactions with negligible loss of activity. Finally, MTbPDT3 was successfully employed in the expedient synthesis of several nucleoside analogues. Taken together, our results support the notion that TbPDT has good potential as an industrial biocatalyst for the synthesis of a wide range of therapeutic nucleosides through an efficient and environmentally friendly methodology.
